Table 2.
Drug therapy problems identified in diabetes management (n = 110).
| Types of Problems | n = 110 |
|---|---|
| According to EU(7) PIM List | |
| Long-acting sulphonylureas (glibenclamide, glimepiride) | 4 (3.6%) |
| Acarbose | 3 (2.7%) |
| Sliding-scale insulin | 5 (4.6%) |
| Contraindication | 2 (1.8%) |
| Overdose | |
| No adjustment to renal function | 20 (18.2%) |
| Medication used at excessively high dose | 10 (9.1%) |
| Underdose | 14 (12.7%) |
| Medication not indicated | |
| Overly tight glycemic control relative to glycemic targets | 22 (20.0%) |
| Pharmacological redundancy | 1 (0.9%) |
| Liraglutide in a patient over 75 years | 1 (0.9%) |
| Indication not treated or insufficiently treated | 4 (3.6%) |
| Hypoglycemia | 10 (9.1%) |
| Subtotal: patients with at least 1 DTP without taking into account Acarbose and Liraglutide | 66 (60.0%) |
| Total (patients with at least 1 DTP) | 67 (60.9%) |
Legend: EU(7) PIM list: European list of potentially inappropriate medications; DTP: drug therapy problems (one patient can have several drug therapy problems). Dosage adjustments for patients with kidney failure (according to the Summaries of Product Characteristics available in 2016): Metformin: 1500 mg maximum per day if creatinine clearance is between 30 and 60 mL/min; contraindicated if creatinine clearance is <30 mL/ min). Sitagliptin: 50 mg maximum per day if creatinine clearance is between 30 and 50 mL/min; 25 mg maximum per day if creatinine clearance is <30 mL/ min). Acarbose: contraindicated if creatinine clearance is < 25 mL/min.